Unapproved Eli Lilly Weight Loss Drug Retatrutide Illegally Sold Online

A weight loss drug that exists only in Eli Lilly's laboratories—still years away from any regulatory approval—is already being sold online to American consumers. CBS News investigators found that companies are marketing retatrutide, an experimental medication still in clinical trials, directly to people willing to pay for it, despite the fact that it has never been cleared by the FDA for human use outside of controlled research settings.

Retatrutide belongs to a class of drugs designed to help people lose weight by mimicking hormones that regulate appetite and blood sugar. Eli Lilly is testing it in clinical trials, the standard pathway any new medication must follow before the FDA will consider whether it is safe and effective enough to sell to the public. That process typically takes years. But the drug's promise—and the desperation of people struggling with weight—has created a market that operates entirely outside legal channels.

The investigation found multiple online operations actively selling retatrutide to U.S. customers. These companies are circumventing the entire regulatory framework designed to protect consumers. They market the drug through websites and online platforms, taking orders and payment from Americans seeking a shortcut to weight loss. There is no way for these buyers to know whether what they are receiving is actually retatrutide, whether it is pure, whether it is stored properly, or whether it will do what the sellers claim.

The risks are substantial and largely unknown. Because retatrutide is still experimental, its long-term effects on human health have not been fully documented. People taking it outside of clinical trials have no medical supervision, no baseline health assessments, and no way to report adverse effects to researchers or regulators. If something goes wrong—an unexpected interaction, an organ problem, a serious side effect—there is no safety net. The person taking the drug bears all the risk.

For the companies selling it, the legal exposure is equally serious. Distributing unapproved drugs is a federal crime. The FDA has enforcement authority to pursue these operations, and the Department of Justice can bring criminal charges against the people running them. Buyers, too, face potential legal consequences, though prosecution of individual consumers is less common than prosecution of sellers.

The case of retatrutide illustrates a broader problem in the weight loss drug market. Approved medications like semaglutide and tirzepatide have created such high demand—and such high prices—that a shadow market has emerged. People who cannot afford approved drugs, or who cannot access them through legitimate channels, turn to online sellers offering unapproved alternatives or experimental versions. The sellers exploit that demand, often making claims they cannot substantiate and selling products they cannot guarantee.

Eli Lilly has not publicly commented on the illegal sales of its experimental drug. The company's focus remains on completing clinical trials and seeking FDA approval through proper channels. But the existence of this black market raises questions about how long companies can realistically keep experimental drugs away from consumers once their potential becomes widely known. It also underscores the gap between the pace of drug development and the urgency people feel when facing weight-related health problems.

The FDA has limited resources to police online drug sales, and new operations can emerge quickly once others are shut down. For now, retatrutide remains available to Americans through illegal channels, sold by companies operating in legal gray zones or outright defiance of federal law. Anyone considering purchasing it faces a choice between waiting for legitimate approval and accepting unknown risks from an untested source.